Biotech stalwart Biogen has been living in limbo since the summer, when long-time CEO George Scangos announced his impending resignation. But the revelation of his heir apparent hasn’t exactly galvanized investors and analysts concerned about the company’s future.
Starting Jan. 6, the new Biogen boss will be Chief Commercial Officer Michel Vounatsos — a choice that came as a disappointment to many, as the news sent the company’s shares down more than 2 percent on Monday afternoon.
About the Author Reprints
